title: Structural and functional characteristics of a dominant-negative isoform of porcine MHC class II transactivator.
abstract: The MHC class II transactivator, CIITA, is critical for MHC class II gene expression in all species studied to date. We isolated an interferon (IFN)-gamma-inducible isoform of porcine CIITA (pCIITA') encoding a protein of 566 amino acids (aa) with significant homology to human CIITA (hCIITA). Analysis indicated that pCIITA' lacks the entire GTP-binding domain that is important for nuclear translocation and activation of target genes by hCIITA. In pCIITA' this region is replaced by a 14-aa motif with homology to several signalling peptide sequences. Expression of pCIITA' in porcine (ST-IOWA) and human (HeLa) cell lines resulted in suppression of IFN-gamma-stimulated MHC class II gene expression, at the protein and mRNA levels. We also identified two IFN-gamma-inducible variants of hCIITA, hCIITAlo and hCIITA' from Hela cells, both exhibiting dominant-negative suppression of MHC class II gene expression. Interestingly, hCIITA' encodes a predicted protein of 546 aa with a strikingly similar organization to pCIITA' including the 14-aa GTP-binding domain-replacement motif in which 10 out of 14 amino acids are identical to the pig sequence. Expression of hCIITA' and hCIITAlo sequences in Hela cells suppressed IFN-gamma-induced MHC class II gene expression. hCIITAlo, a predicted 303-aa protein with deleted GTP-binding and carboxy-terminal domain, displayed a more subtle suppression of IFN-gamma-induced MHC class II expression. These in vitro data indicate that there may be a role in vivo for isoforms of CIITA that can suppress full-length CIITA-mediated MHC class II gene expression. Both humans and now, potentially, pigs are candidate donors for organ and tissue allografts and xenografts, respectively. Regulation of MHC class II gene expression by manipulation of CIITA isoform expression in humans and pigs may provide a useful strategy for attenuation of T-cell-mediated cellular rejection.
authors.affiliation: Imutran Limited, A Novartis Pharma AG Co, Cambridge, UK. gary.quinn@immergebt.com
authors.forename: G
authors.initials: G
authors.lastname: Quinn
authors.forename: R
authors.initials: R
authors.lastname: Bower
authors.forename: G
authors.initials: G
authors.lastname: Dos-Santos Cruz
authors.forename: M
authors.initials: M
authors.lastname: Giovino
authors.forename: Y
authors.initials: Y
authors.lastname: Xu
authors.forename: C
authors.initials: C
authors.lastname: Patience
authors.forename: H-J
authors.initials: HJ
authors.lastname: Schuurman
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D001483:Base Sequence; D005799:Genes, Dominant; D000949:Histocompatibility Antigens Class II / Q000096:biosynthesis / Q000235:genetics; D006801:Humans; D008969:Molecular Sequence Data; D009687:Nuclear Proteins / Q000235:genetics* / Q000502:physiology*; D020033:Protein Isoforms; D017385:Sequence Homology; D013154:Spleen / Q000502:physiology; D013552:Swine / Q000235:genetics / Q000502:physiology; D015534:Trans-Activators / Q000235:genetics* / Q000502:physiology*; D015533:Transcriptional Activation
chemical_list: D000949:Histocompatibility Antigens Class II; C083728:MHC class II transactivator protein; D009687:Nuclear Proteins; D020033:Protein Isoforms; D015534:Trans-Activators